XWARCTX
Market cap47mUSD
Dec 23, Last price
41.80PLN
1D
0.00%
1Q
-43.82%
IPO
-72.86%
Name
Captor Therapeutics SA
Chart & Performance
P/E
—
P/S
14.80
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.36%
Rev. gr., 5y
283.09%
Revenues
13m
+44.15%
Net income
-71m
L+111.18%
CFO
-52m
L+127.49%
Profile
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
IPO date
Apr 19, 2021
Employees
111
Domiciled in
PL
Incorporated in
PL
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 13,201 44.15% | 9,158 129.75% | 3,986 | ||||
Cost of revenue | 93,322 | 65,800 | 43,401 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (80,121) | (56,642) | (39,415) | ||||
NOPBT Margin | |||||||
Operating Taxes | 57 | (2,470) | 400 | ||||
Tax Rate | |||||||
NOPAT | (80,178) | (54,172) | (39,815) | ||||
Net income | (70,584) 111.18% | (33,424) 1.37% | (32,972) 151.94% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 40,008 | 4 | 148,240 | ||||
BB yield | -8.70% | 0.00% | -19.97% | ||||
| Debt | |||||||
Debt current | 2,531 | 3,717 | 5,241 | ||||
Long-term debt | 5,025 | 10,187 | 11,121 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 96 | 51 | 33 | ||||
Net debt | (68,148) | (76,986) | (101,581) | ||||
| Cash flow | |||||||
Cash from operating activities | (52,204) | (22,948) | (28,473) | ||||
CAPEX | (3,005) | (892) | (5,113) | ||||
Cash from investing activities | 19,931 | (17,630) | (5,113) | ||||
Cash from financing activities | 36,941 | (6,329) | 140,875 | ||||
FCF | (76,866) | (51,499) | (42,741) | ||||
| Balance | |||||||
Cash | 75,704 | 90,890 | 117,943 | ||||
Long term investments | |||||||
Excess cash | 75,044 | 90,432 | 117,744 | ||||
Stockholders' equity | (139,663) | (73,709) | (45,830) | ||||
Invested Capital | 212,757 | 175,685 | 177,349 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 4,646 | 4,168 | 4,128 | ||||
Price | 99.00 -38.13% | 160.00 -11.01% | 179.80 | ||||
Market cap | 459,925 -31.04% | 666,901 -10.15% | 742,209 | ||||
EV | 391,777 | 589,915 | 640,628 | ||||
EBITDA | (74,681) | (49,548) | (32,060) | ||||
EV/EBITDA | |||||||
Interest | 323 | 321 | 400 | ||||
Interest/NOPBT | |||||||